A Phase 3, Reandomized, Double-blind, Controlled Study Evaluating the Efficacy oand Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous f

Sponsored by Vertex Pharmaceuticals, Incorporated